Articles related to ANTIVIRALS

The FDA has approved the first generic version of baloxavir marboxil, a single-dose influenza antiviral noninferior to oseltamivir, ahead of the 2026-2027 flu season.

Antiviral therapy initiated within 48 hours of symptom onset can reduce illness duration by 1-2 days, highlighting the importance of early recognition and intervention in high-risk populations.

Immunocompromised individuals are at a 6 to 11 times higher risk of developing herpes zoster compared to the general population, with hematopoietic stem cell transplant recipients facing the highest risk.

Integrating telehealth into opioid treatment programs drastically improves hepatitis C cure rates, particularly among underserved populations, by facilitating seamless access to DAAs and continuous follow-up care.

In the battle against recurrent herpes simplex virus infections, chronic suppressive therapy emerges as a pivotal strategy, diminishing both the physical burden of outbreaks and the psychological weight of potential transmission.

In the high-risk patient cohort, the combination of baricitinib and remdesivir not only demonstrated a significant reduction in mortality and progression to invasive mechanical ventilation but also showcased an enhanced recovery trajectory.